fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Pooled analysis of two Phase III Trials shows Halaven® (Eribulin) improves survival in advanced breast cancer

Written by | 26 Jun 2014

Significant survival benefit observed in women with HER2 negative breast cancer – ASCO Press Release.

Lenvatinib Phase III results show significant improvement in progression-free survival in people with Radioiodine-Refractory differentiated Thyroid Cancer

Written by | 26 Jun 2014

Pivotal phase III data for lenvatinib to be presented in a Head and Neck Cancer oral session at American Society of Clinical Oncology congress (ASCO) – Press Release.

Focused ultrasound reduces cancer pain

Written by | 12 Jun 2014

Non-invasive focused ultrasound thermal therapy reduces pain from bone metastases.  When cancer progresses and spreads to the bone, patients often suffer debilitating pain. Now, a new phase III… read more.

Treatment outcome according to tumour RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab.

Written by | 5 Jun 2014

Adapted from Abstract 3506, which was submitted to ASCO Congress 2014 Treatment outcome according to tumour RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized… read more.

Pancreatic cancer fatalities set to rise

Written by | 23 May 2014

World Health Matters by Gary Finnegan – Italy – Death rates from pancreatic cancer are predicted to increase in men and women in 2014 and beyond, according to… read more.

​Mind over matter: Beating pain and painkillers – Mindfulness reduces pain and opioid misuse

Written by | 4 Mar 2014

University of Utah researcher Eric Garland (pictured) developed a new mindfulness-focused treatment for people with chronic pain that can effectively reduce pain and misuse of opioid painkillers.

Press Release: Emerging data from CLL10 presented at ASH suggests Levact® (bendamustine) and rituximab as new treatment option for fit elderly CLL patients

Written by | 7 Feb 2014

New interim analysis study findings presented for the first time today at the 55th American Society of Hematology (ASH) Annual Meeting in New Orleans suggest bendamustine and rituximab… read more.

Pandemic of untreated cancer pain due to over-regulation of pain medicines

Written by | 16 Dec 2013

A ground-breaking international collaborative survey, published today in Annals of Oncology, shows that more than half of the world’s population live in countries where regulations that aim to… read more.

Novel agent shows promise for non-small cell lung cancer

Written by | 3 Dec 2013

by Bruce Sylvester – Researchers report that an experimental cancer drug which has shown efficacy in  treating melanoma also shows promise  in treating non-small cell lung cancer, a… read more.

Poster Session at ECC 2013 – Younger patients at high risk

Written by | 2 Dec 2013

Discussion of the abstract by Dr Christopher Lieu, MD, Assistant professor at the University of Colorado.  Younger patients with colorectal cancer that has spread (metastasised) to other parts… read more.

Poster Session at ECC 2013 – How to endure life during treatment for colorectal cancer

Written by | 29 Nov 2013

Birgitte Pedersen et al, Vejle Hospital, Denmark.  Patients with colorectal cancer (CRC) face huge challenges in their everyday lives as a result of their condition and treatments.

Poster Session at ECC 2013 – Biology of the tumour key to treatment

Written by | 28 Nov 2013

Discussion of the abstract by Dr Zoran Gatalica, Adjunct Professor of Pathology at Creighton University School of Medicine .

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.